Recipharm launches standalone serialisation service

5 Jul 2018

Company will be able to add 2D codes, human-readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.

Recipharm has launched its standalone serialisation service ahead of the introduction of the EU Falsified Medicines Directive (FMD).

Recipharm launches standalone serialisation service

The new service is designed to offer pharmaceutical companies access to Recipharm’s serialisation capabilities as a standalone service due to increasing concerns that many will not be ready for the February 2019 compliance deadline.

Recipharm will be able to add 2D codes, human-readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.

Staffan Widengren, Director of Corporate Projects at Recipharm and Head of the Global Steering Committee for Recipharm’s serialisation programme said: ”This new offering is the latest phase in our company-wide serialisation project which was launched in 2016 following a EUR 40 million investment.”

”In recent years, Recipharm has become known for taking a lead in the serialisation challenge. As the deadline gets closer we’re seeing more and more companies ask if we can provide an outsourced serialisation service that caters for the new requirements, even if the product itself is not manufactured within Recipharm it made sense to allow customers who were struggling with their existing provider to get access to our solution.”

”Implementing these measures independently across packaging lines to ensure compliance is a relatively straightforward process when using offline equipment. Our experience of serialisation means we can ensure compliance quickly and efficiently for our customers.”

Read More

Related news

Concept Life Sciences extends GLP accreditation to support regulatory studies

Concept Life Sciences extends GLP accreditation to support regulatory studies

10 Nov 2018

Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries.

Read more 
Sartorius receives award for outstanding performance in its production chain

Sartorius receives award for outstanding performance in its production chain

8 Nov 2018

Company's manufacturing building for laboratory instruments in Göttingen wins the Global Excellence in Operations Award.

Read more 
Record growth at The Wasdell Group

Record growth at The Wasdell Group

7 Nov 2018

Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.

Read more 
bioLIVE to merge with BioProduction Congress for 2019 event

bioLIVE to merge with BioProduction Congress for 2019 event

7 Nov 2018

BioProduction’s content platform will be added to the bioLIVE exhibition, creating one of the world’s largest event hubs for the bio industry.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more 
Croda opens its Centre of Innovation for marine biotechnology

Croda opens its Centre of Innovation for marine biotechnology

5 Nov 2018

The new Centre of Innovation for Marine Biotechnology will accelerate the company’s research and product development program to identify sustainable, natural sources of functional ingredients.

Read more 
Plasticell receives EU funding to advance neurodegenerative disease research

Plasticell receives EU funding to advance neurodegenerative disease research

1 Nov 2018

Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.

Read more 
DSCSA one-month countdown!

DSCSA one-month countdown!

30 Oct 2018

With only a month to go, it really is too late to start trying to develop an in-house solution.

Read more 
Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

30 Oct 2018

Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.

Read more 
Elpis Biomed human cell models could potentially replace animal experiments in drug discovery

Elpis Biomed human cell models could potentially replace animal experiments in drug discovery

28 Oct 2018

OPTi-OX technology allows the company to produce human cells of unprecedented quality, purity, and consistency.

Read more